pharma · Glaucoma · Macular Edema
Allergan Pharmaceuticals International
Allergan Pharmaceuticals International Limited
Allergan Pharmaceuticals International clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Dublin, IE
- Programs
- 13
- Drugs
- 15
- Patents
- 25
Allergan Pharmaceuticals International projects
8 ClinicalTrials.gov programs sponsored by Allergan Pharmaceuticals International.
Allergan Pharmaceuticals International has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
700 µg Dexamethasone
Allergan Pharmaceuticals International Limited
Macular Edema
1 trial -
AGN-195263
Allergan Pharmaceuticals International Limited
Dry Eye Syndromes
1 trial -
Abicipar Pegol
Allergan Pharmaceuticals International Limited
Macular Degeneration
1 trial -
Placebo
Allergan Pharmaceuticals International Limited
Gastroparesis
3 trials -
Rapastinel
Allergan Pharmaceuticals International Limited
Depressive Disorder, Major
1 trial -
XEN45
Allergan Pharmaceuticals International Limited
Glaucoma
1 trial -
bimatoprost ophthalmic solution formulation A
Allergan Pharmaceuticals International Limited
Glaucoma
1 trial -
botulinum toxin Type A
Allergan Pharmaceuticals International Limited
Pediatrics
4 trials
Frequently asked questions
How many clinical projects does Allergan Pharmaceuticals International have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.